Skip to main content
. Author manuscript; available in PMC: 2013 Aug 2.
Published in final edited form as: Immunol Invest. 2012;41(0):680–710. doi: 10.3109/08820139.2012.703745

Figure 6.

Figure 6

Three mouse tumor models display dose-dependent reductions in splenic MDSCs (A) and normalized T cell function (B) during sunitinib treatment. Note the range in MDSC sensitivity, with 4T1 model displaying splenic MDSC resistance at the 20 mg/kg dose.